Breakthrough cancer pain Archives | Cannabiz

Replacement funding falls through as Nexalis’ studies remain suspended

by Adam Sheldon July 6, 2026July 6, 2026

Nexalis Therapeutics’ two clinical studies exploring inhaled cannabinoid treatments for breakthrough cancer pain and panic disorder […]

News in brief: Nexalis advances IRX-616a and IRX-211 programs; Vitura heralds Doctors on Demand growth; Elixinol improves cash flow

by Adam Sheldon April 20, 2026June 11, 2026

Nexalis outlines 2026 plan as IRX shares jump 35%

by Adam Sheldon February 17, 2026February 19, 2026

InhaleRx eyes big pharma deal and ponders product launch through SAS

by Steve Jones March 18, 2025March 18, 2025

InhaleRx prepares for pivotal trial in quest to provide relief from breakthrough cancer pain

by cannabiz team January 29, 2025January 31, 2025